Surgeons save bones: An algorithm for orthopedic surgeons managing secondary fracture prevention

Archives of Orthopaedic and Trauma Surgery

Volumn 133, Issue 8, 2013, Pages 1101-1108

  Gosch, M ^a   Kammerlander, C ^b   Roth, T ^b   Doshi, H K ^c   Gasser, R W ^d   Blauth, M ^b  

^a Hospital Hochzirl   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c TAN TOCK SENG HOSPITAL   (Singapore)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Fragility fracture; Osteoporosis; Osteoporosis treatment; Secondary fracture prevention; Treatment algorithm

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; PARATHYROID HORMONE[1-34]; RALOXIFENE; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

AGE; ALGORITHM; ARTICLE; BONE DENSITY; CALCIUM HOMEOSTASIS; CALCIUM INTAKE; CLINICAL ASSESSMENT TOOL; COMORBIDITY; DIET SUPPLEMENTATION; DRUG CHOICE; DRUG CONTRAINDICATION; FRAGILITY FRACTURE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; KIDNEY FUNCTION; LIFE EXPECTANCY; ORTHOPEDIC SURGEON; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT FAILURE; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

AGED; ALGORITHMS; FEMALE; HUMANS; MIDDLE AGED; ORTHOPEDIC PROCEDURES; ORTHOPEDICS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PRACTICE GUIDELINES AS TOPIC;

EID: 84880923140     PISSN: 09368051     EISSN: 14343916     Source Type: Journal    
DOI: 10.1007/s00402-013-1774-x     Document Type: Article

References (49)

1. WHO (1998) Guidelines for preclinical evaluation and clinical trials in osteoporosis. WHO, Geneva, p 59
2. US Department of Health and Humane Services (DHHS) (2003) Report of the surgeon general's workshop on osteoporosis and bone health. Available at http://www.surgeongeneral.gov/library/bonehealth/index.html Accessed 26 Jan 2013, pp 1-100
3. Reginster JY, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38(2 Suppl 1):S4-S9 (Pubitemid 43190767)
4. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8(6):599-603 (Pubitemid 28566977)
5. Häussler B, Gothe H, Göl D, Glaeske G, Pientka L, Felsenberg D (2007) Epidemiology, treatment and costs of osteoporosis in Germany - the Bone EVA Study. Osteoporos Int 18(1):77-84 (Pubitemid 44885498)
6. Johnell K, Fastbom J (2009) Undertreatment of osteoporosis in the oldest old? A nationwide study of over 700,000 older people. Arch Osteoporos 4((1-2)):17-23 Epub 2009 Mar 19
7. Kammerlander C, Gosch M, Kammerlander-Knauer U, Luger TJ, Blauth M, Roth T (2011) Long-term functional outcome in geriatric hip fracture patients. Arch Orthop Trauma Surg 131(10):1435-1444
8. Jennings LA, Auerbach AD, Maselli J, Pekow PS, Lindenauer PK, Lee SJ (2010) Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 58:650-657
9. Fonarow GC, Gheorghiade M, Abraham WT (2004) Importance of in-hospital initiation of evidence based medical therapies for heart failure-a review. Am J Cardiol 94(9):1155-1160 (Pubitemid 39424219)
10. Muhlestein JB, Horne BD, Bair TL, Li Q, Madsen TE, Pearson RR, Anderson JL (2001) Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 87(3):257-261 (Pubitemid 32144862)
11. Center JR, Bliuc D, Nguyen TV, Eisman JA (2007) Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 297(4):387-394 (Pubitemid 46155800)
12. Queally JM, Kiernan C, Shaikh M, Rowan F, Bennett D (2012) Initiation of osteoporosis assessment in the fracture clinic results in improved osteoporosis management: a randomised controlled trial. Osteoporos Int. (Epub ahead of print) PubMed PMID: 23242431
13. Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A, Mitchell PJ, Silverman S, Singleton R, Siris E (2012) Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 27(10):2039-2046
14. Kammerlander C, Gosch M, Blauth M, Lechleitner M, Luger TJ, Roth T (2011) The tyrolean geriatric fracture center: an orthogeriatric co-management model. Z Gerontol Geriatr 44(6):363-367
15. Gosch M, Roth T, Kammerlander C, Joosten-Gstrein B, Benvenuti-Falger U, Blauth M, Lechleitner M (2011) Treatment of osteoporosis in postmenopausal hip fracture patients after geriatric rehabilitation: changes over the last decade. Z Gerontol Geriatr 44(6):381-386
16. Premaor MO, Pilbrow L, Tonkin C, Adams M, Parker RA, Compston J (2010) Low rates of treatment in postmenopausal women with a history of low trauma fractures: results of audit in a fracture liaison service. QJM 103(1):33-40
17. Kates SL, Mendelson DA, Friedman SM (2010) Co-managed care for fragility hip fractures (rochester model). Osteoporos Int 21(Suppl 4):S621-S625
18. Chakravarthy J, Ali A, Iyengar S, Porter K (2008) Secondary prevention of fragility fractures by orthopaedic teams in the UK: a national survey. Int J Clin Pract 62(3):382-387 (Pubitemid 351197417)
19. Ringe JD, Doherty JG (2010) Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int 30(7):863-869
20. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) On behalf of the scientific advisory board of the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) and the committee of scientific advisors of the international osteoporosis foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23-57
21. Gates BJ, Sonnett TE, Duvall CA, Dobbins EK (2009) Review of osteoporosis pharmacotherapy for geriatric patients. Am J Geriatr Pharmacother 7(6):293-323
22. Rabar S, Lau R, O'Flynn N, Li L, Barry P (2012) Guideline development group. Risk assessment of fragility fractures: summary of NICE guidance. BMJ 345:e3698. doi: 10.1136/bmj.e3698
23. Bogoch ER, Elliot-Gibson V, Beaton DE, Jamal SA, Josse RG, Murray TM (2006) Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am 88(1):25-34 (Pubitemid 43062769)
24. http://www.shef.ac.uk/FRAX. Accessed 11 May 2013
25. Brown EM, Hebert SC (1997) Calcium-receptor-regulated parathyroid and renal function. Bone 20(4):303-309 (Pubitemid 27196653)
26. Khairallah W, Fawaz A, Brown EM, El-Hajj Fuleihan G (2007) Hypercalcemia and diabetes insipidus in a patient previously treated with lithium. Nat Clin Pract Nephrol 3(7):397-404 (Pubitemid 46987806)
27. http://www.ema.europe.eu. Accessed 26 Jan 2013
28. Chauvelier S, Péquignot R, Amzal A, Hanon O, Belmin J (2012) Comparison between the three most popular formulae to estimate renal function, in subjects 75 years of age or older. Drugs Aging 29(11):885-890
29. Verbrugge FH, Gielen E, Milisen K, Boonen S (2012) Who should receive calcium and vitamin D supplementation? Age Ageing 41(5):576-580
30. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Endocrine society. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911-1930
31. Sinha A, Cheetham TD, Pearce SH (2012) Prevention and treatment of vitamin D deficiency. Calcif Tissue Int. (Epub ahead of print) PubMed PMID: 23124916
32. Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 92(4):1415-1423 (Pubitemid 46556419)
33. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R, Wong JB, Egli A, Kiel DP, Henschkowski J (2009) Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 339:b3692. doi: 10.1136/bmj.b3692
34. Curtis JR, Arora T, Matthews RS, Taylor A, Becker DJ, Colon-Emeric C, Kilgore ML, Morrisey MA, Saag KG, Safford MM, Warriner A, Delzell E (2010) Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. J Am Med Dir Assoc 11(8):584-591
35. Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245-1251 (Pubitemid 24361532)
36. Mahoney FI, Barthel DW (1965) Functional evaluation: the barthel index. Md State Med J 14:61-65
37. Parker MJ, Palmer CR (1993) A new mobility score for predicting mortality after hip fracture. J Bone Jt Surg Br Vol 75(5):797-798 (Pubitemid 23267950)
38. Nakazawa A, Nakamura K, Kitamura K, Yoshizawa Y (2012) Association between activities of daily living and mortality among institutionalized elderly adults in Japan. J Epidemiol 22(6):501-507
39. Kammerlander C, Gosch M, Kammelrander-Knauer U, Luger TJ, Blauth M, Roth T (2011) Long-term functional outcome in geriatric hip fracture patients. Arch Orthop Trauma Surg 131(10):1435-1444
40. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, for the HORIZON Recurrent fracture trial (2007) Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 357:nihpa40967 (Pubitemid 350044800)
41. Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW (2010) Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 58(2):292-299
42. Reid IR, Black DM, Eastell R, Bucci-Rechtweg C, Su G, Hue TF, Mesenbrink P, Lyles KW, Boonen S (2013) For the HORIZON pivotal fracture trial HORIZON recurrent fracture trial steering committees. Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams. J Clin Endocrinol Metab (Epub ahead of print) PubMed PMID: 23293335
43. Akehurst R, Brereton N, Ariely R, Lusa T, Groot M, Foss P, Boonen S (2011) The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands. J Med Econ 14(1):53-64
44. Goldhahn J, Féron JM, Kanis J, Papapoulos S, Reginster JY, Rizzoli R, Dere W, Mitlak B, Tsouderos Y, Boonen S (2012) Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int 90(5):343-353
45. Eriksen EF, Lyles KW, Colón-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P (2009) Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 24(7):1308-1313
46. Amanat N, McDonald M, Godfrey C, Bilston L, Little D (2007) Optimal timing of a single dose of zoledronic acid to increase strenght in rat fracture repair. J Bone Miner Res 22:867-876 (Pubitemid 351339747)
47. http://www.nice.org.uk/nicemedia/live/11748/42447/42447.pdf. Accessed 4 Jan 2013
48. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr (2012) American college of chest physicians. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl) 9th edn: e278S-e325S
49. Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, Eastell R, Eriksen EF, Gonzalez-Macias J, Liberman UA, Wahl DA, Seeman E, Kanis JA, Cooper C (2012) IOF CSA inadequate responders working group treatment failure in osteoporosis. Osteoporos Int 23(12):2769-2774